Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adaptive Radiation Therapy in the 0-7-21 Regimen: A Retrospective Study of Tumor Volumetric Response.

Advances in radiation oncology·2026
Same author

A Prospective Population-Based Study of Chimeric Antigen Receptor T-Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma.

Current oncology (Toronto, Ont.)·2026
Same author

Ultra-high dose radiation for Liver metastasis using MR-guided TReatment with stereotactic Ablative Single-fraction (ULTRAS): Study protocol for a phase III randomized controlled trial.

Contemporary clinical trials·2026
Same author

Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) - a phase 2 study: acute safety and quality of life outcomes.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

How Cancer Online Support Groups Work, for Whom, and in What Circumstances: Realist Review.

Journal of medical Internet research·2026
Same author

The Impact of Ontario's Virtual Care Payment Model on Cancer Care: A Natural Policy Experiment.

Journal of medical Internet research·2026
Same journal

Prognostic Factors for Relapse and Mortality Risk in Chilean Patients With Testicular Cancer: A Retrospective Cohort Study.

JCO global oncology·2026
Same journal

Adherence to Survivorship Care Visits in Patients With Cervical Cancer in Botswana.

JCO global oncology·2026
Same journal

Comparative Analysis of Breast Cancer Care Disparities in Argentina: Diagnosis, Treatment Timeliness, and Cyclin-Dependent Kinase Inhibitor Implications.

JCO global oncology·2026
Same journal

Socioeconomic Outcomes of Childhood Cancer Survivors in India: A Cross-Sectional Study From a Tertiary Care Childhood Cancer Survivorship Program.

JCO global oncology·2026
Same journal

<i>Supportive Care in What</i>? Myths and Misconceptions That Prevent the Provision of Excellent Cancer Care.

JCO global oncology·2026
Same journal

Physician Perceptions Toward Palliative Care Integration in Childhood Cancer Care in Asia Pacific.

JCO global oncology·2026
See all related articles

Related Experiment Video

Updated: Mar 19, 2026

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.8K

Global Approach to Oncology Leadership: The GOLD Program.

Meredith Elana Giuliani1,2,3, Tina Papadakos2,3, Sun Choi2

  • 1Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Canada.

JCO Global Oncology
|March 17, 2026
PubMed
Summary
This summary is machine-generated.

The Princess Margaret Global Oncology Leadership Development (GOLD) program effectively enhances leadership skills for cancer care professionals worldwide. This accessible, inclusive training improves confidence and preparedness for global oncology challenges.

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.3K
Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
05:33

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation

Published on: September 6, 2024

2.4K

Related Experiment Videos

Last Updated: Mar 19, 2026

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.8K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.3K
Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
05:33

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation

Published on: September 6, 2024

2.4K

Area of Science:

  • Global Health
  • Oncology Leadership
  • Healthcare Education

Background:

  • Leadership is crucial for addressing complex global cancer care challenges.
  • Healthcare providers need effective leadership skills for diverse and resource-constrained settings.
  • The Princess Margaret Global Oncology Leadership Development (GOLD) program offers accessible, interdisciplinary training.

Purpose of the Study:

  • To describe the development, implementation, and outcomes of the first five years of the GOLD program.
  • To assess the impact of leadership training on oncology fellows.
  • To evaluate the effectiveness of an inclusive leadership program in global oncology.

Main Methods:

  • A hybrid, multiformat leadership training program integrating experiential learning and mentorship.
  • Free and open access for all oncology fellows to eliminate barriers.
  • Statistical analysis (McNemar's test, T-tests) and inductive thematic analysis of interviews and surveys.

Main Results:

  • Statistically significant improvements in confidence across 24 leadership competencies.
  • Four key themes emerged: improved preparedness, sustained global networking, enhanced cross-contextual understanding, and intrapersonal skill growth.
  • No associations found between confidence gains and participants' geographic or economic backgrounds.

Conclusions:

  • The GOLD program proves the effectiveness of inclusive, experiential leadership training in oncology.
  • Removing access barriers and prioritizing diversity cultivates future global cancer leaders.
  • Ongoing evaluation ensures program relevance for equitable and effective worldwide cancer care leadership.